Tale of Two sons - Nobelar and Excelar and the blurring edge between them

Left main coronary artery disease (LMCAD) has low incidence but foreshadow a high prognostic risk merely due to the myocardial territory it supplies. Coronary artery bypass grafting (CABG) has been the standard of treatment for LMCAD. Recently, two major trials—NOBEL and EXCEL—with contradicting results have been published. I will not wade into the accusations of malfeasance, but the bottom line is that, superiority of percutaneous coronary interventions (PCI) to CABG is yet to be proved. Heart-team approach has been discussed in every aspect, but in real-world scenario, to what extent, and in what manner the same is practised, remains a question. We need an objective type of heart-team approach than a subjective heart-team approach.